Sanofi sues to protect Lantus

Share this article:

Sanofi has filed a patent lawsuit against Eli Lilly, putting in place a 30-month waiting period for Eli Lilly's Lantus biosimilar.

The lawsuit is not a surprise: Lilly indicated in last week's earnings call that it was expected, because filing its FDA generics review application opened up a notification window, which alerted Sanofi that a potential competitor was on the block. It also put in place a stay that keeps Lilly's drug from progressing through the regulatory pathway.

Sanofi's suit comes with good reason—the diabetes medication earned the company almost $2 billion in third-quarter sales. In 2012, this same drug added just under $7 billion to its global coffers.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA lifts OncoMed partial hold

The FDA froze the clinical trial of anti-Fzd7 vantictumab in July over concern about "bone-related adverse events."

Research links estrogen and binge eating

Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.